Suramin is a medication used to treat African sleeping sickness and river blindness. It is the treatment of choice for sleeping sickness without central nervous system involvement. It is given by injection into a vein. Common side effects include nausea, + some more technical info: suramin is a polysulfonated naphthylurea that acts as a broad-spectrum inhibitor of multiple parasite and host enzymes and growth factor interactions, displays strong plasma protein binding, and has a prolonged terminal elimination phase requiring careful dosing and monitoring. Clinically it is administered intravenously with dosing adjusted to body weight and renal function, and adverse effects beyond nausea commonly include vomiting, skin reactions, reversible renal impairment, and rare neurologic or hematologic changes, so laboratory monitoring of renal and liver function during treatment is standard practice.
Parent: Suramin
Commercial and clinical-grade suramin batches are controlled for related substances and degradation products using validated HPLC and LC-MS methods; well-controlled active pharmaceutical ingredient lots typically show assay purity greater than 95 percent with individual related compounds present at low trace levels, commonly under 0.5 to 1.0 percent by area, and total related compounds maintained under about 2.0 to 3.0 percent, depending on the supplier specification; known related species include hydrolysis and desulfonation products, urea cleavage fragments and minor synthesis intermediates, while routine quality testing also monitors residual solvents and elemental impurities by appropriate methods such as GC, ICP-MS and NMR for structural confirmation.
Suramin is commonly encountered as suramin sodium and has been marketed historically under trade names such as Germanin in some regions.
Cost varies by formulation, regulatory status and supplier; clinical-grade injectable suramin obtained through regulated channels or specialty suppliers can run from several hundred to a few thousand US dollars per treatment dose, while research-grade reagent material is typically priced by the gram and is substantially less; exact pricing requires inquiry with manufacturers or distributors.
Suramin has a multifactorial mechanism that is not fully restricted to a single target; it binds to proteins and polyanionic sites interfering with parasite enzymes, energy metabolism and receptor-mediated processes, and can inhibit multiple host and parasite enzymes and growth factor interactions, resulting in antiparasitic activity against Trypanosoma species.
Suramin is not widely marketed for common outpatient use in the United States; access for clinical treatment typically requires appropriate regulatory authorization such as investigational or compassionate use protocols, and research-grade suramin is available from licensed suppliers for laboratory use.
